歐康維視生物-B(01477.HK):建議於公開市場購回股份
格隆匯11月29日丨歐康維視生物-B(01477.HK)發佈公吿,董事會有意於適時行使其根據股東向董事會授出的一般授權,以購回公司股份的權力,視乎市況,以不時在公開市場上以不超過1億港元的總價購回股份。根據公司於2023年6月16日舉行的股東周年大會上通過的普通決議案,股東向董事會授出購回股份的一般授權,以購回最多6907.11萬股股份,佔該股東周年大會日期已發行股份總數的10%。公司隨後將於合理可行的情況下儘快註銷購回的股份(如有)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.